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Executive summary 
 
We are very conscious that, within the European Union, various terms are used to 
refer to the many diverse communities living in the member states.  We prefer the 
term Black and minority ethnic (BME) groups / communities.  This reflects that our 
concern is not only with those for whom 'Black' is a political term, denoting those who 
identify around a basis of skin colour distinction or who may face discrimination 
because of this or their culture:   'Black and minority ethnic' also acknowledges the 
diversity that exists within these communities, and includes a wider range of those 
who may not consider their identity to be ‘Black,’ but who nevertheless constitute a 
distinct ethnic group.  Centre for Ethnicity and Health, University of Central Lancashire, Preston, UK. 
 
Aim 
 
The aim of the study was to examine drug use amongst Black and minority ethnic 
(BME) communities in the European Union (EU) and Norway in order to give an 
overview of the situation and its consequences and correlates;  to compare the drug 
use of BME groups with that of the rest of the population;  to identify key points 
relevant to policy-makers;  and to suggest further work to fill information gaps. 
 
Methods 
 
Much of knowledge base on the drug use of BME communities is undocumented.  To 
overcome this significant barrier to data collection and to begin to acquire a picture of 
the situation across 16 countries, the research method used 'key players' as 
informants.  Previous work on drug use amongst BME communities by the Centre for 
Ethnicity and Health has shown that informants should not be restricted to those 
working in the drugs field in some capacity (as service providers or as researchers, 
for example):  a diverse range of others involved in aspects of the health and welfare 
of BME communities - such as BME community organisations, teachers, general 
health and social services, the police, regional and local government services, youth 
services, and so on - also have valuable information about drug use amongst these 
communities.  
 
Key messages were extracted from EMCDDA's previous work on this issue and used 
to devise a questionnaire for each country.  Respondents were asked how accurate 
they thought a series of statements were and to add any other information they had 
from, for example, academic journal papers, research reports, the media, websites, 
and personal experience.  Details of pertinent documents and contact details of other 
potential informants were also requested.  The relevant questionnaire was sent to 
individuals and organisations identified from databases of those working in the drugs 
field and/or with BME groups, and to new contacts suggested by respondents.  To 
maximise the response rate, each questionnaire was translated into the main 
language of the country it concerned. 
 
Responses 
 
By the end of the study, questionnaires had been sent to 1,122 potential informants.  
The overall response rate was at least 28.7% (322) or 1 in 3.5, a high rate for a 
postal/email survey (in some cases, questionnaires were sent to several members of     
the same organisation, but there was just one response on behalf of the whole 
organisation).  Three-quarters of respondents (239) completed the questionnaire 
and/or provided information in another form, and a total of 302 further contact details 
of organisations or individuals were received.  The key player method resulted in 
39% (125) of all responses coming from outside the drug service and drug research 
fields, showing the value of the strategy of asking for information from other 
disciplines.   
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Data analysis 
 
The data from informants were collated as profiles for each of the 16 participating 
countries.  A thematic analysis was then performed according to the themes that 
most consistently arose and that are pertinent to the drug use and related issues of 
BME groups at local, national, and EU-wide levels.  The themes are therefore firmly 
grounded in the data received from informants during this study, and consisted of:    
 
the acknowledgement of drug use amongst BME communities and the value 
of ethnic monitoring 
 
the prevalence of drug use amongst BME communities, including data from 
drug services and the criminal justice system 
 
patterns of drug use amongst BME communities, including cultural variations;  
factors specifically affecting their drug use;  the effects of social exclusion;  
myths, scapegoats and stereotypes;  and barriers to drug service access    
 
the research agenda, including the need to confront the hidden nature of drug 
use amongst BME communities;  collect comparable data across the EU;  
consider the most effective methods of expanding the knowledge base;  and 
to disseminate information 
 
drug service development, including examples of good practice. 
 
The thematic analysis allows the following general statements to be made, although 
there is much variation between countries, not only in policy and practice surrounding 
the drug use of, and responses to, BME groups, but also in the knowledge base. 
 
Acknowledgement of drug use in BME communities 
 
It is clear from some of the responses received by this study that, across the EU, 
drug use amongst BME communities is under-researched, unacknowledged, ignored, 
unrecognised, or hidden by some policy-makers, drug researchers, drug service 
planners and commissioners, and by some members of some BME groups 
themselves.   Reasons for this include a fear of accusations of racism by drawing 
attention to drug use in these communities, and a desire to avoid increasing 
stigmatisation of them.  This stance is misguided.  Ignoring or hiding a problem does 
not make it disappear:  it must be confronted in order that appropriate responses can 
be developed.  Many BME groups are already stigmatised as drug users or dealers, 
yet refusing to accept that this behaviour may occur amongst them does nothing to 
decrease the stigmatisation, and obstructs consideration of their drug service needs 
by policy-makers and service planners and commissioners. 
 
Ethnic monitoring 
 
Ethnic monitoring is an extremely sensitive issue, especially when drug use is being 
monitored, and there was a great deal of variation in the approach to this across the 
EU member states.  However, consistent, co-ordinated ethnic monitoring, based on a 
common set of classifications, is a reliable instrument to measure drug service use 
and, importantly, non-use, by drug users.  Analysis of results of ethnic monitoring 
from drug services and drug surveys provide a baseline for improvements to the 
quality of service provision -  including equal access for all drug users and more 
equitable allocation of resources - and can be used to track changes in drug-using 
patterns and in the uptake of drug services. 
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Prevalence 
 
Successive annual reports from EMCDDA on the state of the drugs problem in the 
EU show that, other than for cannabis, the use of which is relatively common and not 
highly stigmatised, prevalence data are less reliable for more hidden patterns of drug 
use such as heroin injecting.  It follows that, because drug use by some BME groups 
is extremely hidden, and because of the lack of research on this issue, the 
prevalence of drug use amongst these groups is currently even more difficult to 
assess.  BME drug users are under-represented in drug treatment statistics and 
over-represented in drug law offence statistics.  Such data alone therefore give an 
extremely distorted picture of the prevalence of drug use and of drug-using patterns, 
yet in some countries, comprise the bulk of the recorded knowledge base.    
 
Drug-using patterns 
 
The link between drug use and social exclusion is well-established, and the evidence 
collected by this study does not indicate that the drug-using patterns of BME groups 
are different from those of socially-excluded, white, indigenous populations.  
However, there are some cultural variations in the types of substances used, and 
some risk factors specifically affecting drug use amongst BME communities, such as 
trauma suffered by those coming from countries where there are wars, and the 
migration experience failing meet expectations.   
 
Myths, stereotypes, and scapegoats surround the drug use of BME groups, but due 
to the lack of research they can neither be confirmed nor denied.  Examples are that 
religion and the 'strong social bonds' in some BME communities are protective 
factors against drug use;  that BME females do not use drugs;  and, fuelled by 
adverse media reports, an over-representation in criminal statistics, and because 
they are highly visible to the white population because of their skin colour, that some 
BME groups are heavily involved in drug distribution. 
  
Barriers to drug service access 
 
BME groups face many barriers to drug treatment, education, and prevention 
services.  These include a lack of cultural sensitivity by the service, a distrust of 
confidentiality, communication problems because of language, a lack of awareness 
of drugs and drug services, the stigma surrounding drug use within their community, 
and the failure of drug services to target BME drug users. 
 
Needs assessments 
 
The usual method of conducting drug needs assessments consists of commissioning 
researchers who 'parachute' into the relevant local communities, ask about their 
drug-related needs, raise expectations that there will be some change, but disappear 
to produce a report that has no long-term impact.   Future research should avoid the 
parachuting model:  it is a missed opportunity that the resources employed in 
traditional needs assessment processes neither involve nor benefit the communities 
whose needs are being assessed.  Fortunately, there are some initiatives within the 
EU that are successfully engaging BME communities in needs assessments and 
these can be used as example of good practice. 
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Development of drug services for Black and minority ethnic groups 
 
Many BME groups are already socially excluded:  failure to consider their drug 
service needs exacerbates this situation.  There is considerable variation in the drug 
services provided for BME groups both within and between member states, but 
across the EU as a whole, drug policy and practice reflect the needs of the white 
indigenous population.  Although the data collected for this study indicate that the 
drug-using patterns of BME groups are not different from those of socially-excluded, 
white, indigenous populations, this does not follow that BME groups can simply 'slot 
into' existing drug services.  Responses may have to be different in order that the 
barriers to drug service access that these groups face can be overcome.   
 
There is a lack of prevalence estimates of drug use amongst BME communities,  
they are under-represented in drug services, and there is a lack of recognition that 
drugs are used by them.  This combination means that acknowledgement that there 
is drug use amongst these communities is an extremely important stage in the 
development of responses.  The lack of evidence of the prevalence of drug use can 
be used as a justification not to address it, yet it is only through acknowledging it that 
debate and further investigation can be initiated.  The way will then be paved for 
responses that will support BME communities through drugs and drug service 
education and awareness-raising activities.  Needs assessments can then take place 
alongside changes within drug services, and, ultimately, evidence of prevalence and 
drug service uptake and retention can be systematically acquired.  This process 
should be monitored throughout via drug service commissioning systems, to ensure 
that the needs of the BME population is being identified and appropriate responses 
are being implemented. 
 
Research and policy-making agendas 
 
The research and policy-making agendas at local, national, and EU-wide levels 
should prioritise investigations into, and responses to: 
  
the reasons for the under-representation of BME groups in drug services 
 
whether or not the commonly-held beliefs about BME groups (such as strong 
social / family bonds and religion are factors that protect against drug use) are 
accurate and, if so, how these protective factors operate 
 
the factors affecting drug-using patterns amongst specific BME groups, such 
as selling drugs precedes use amongst those who are socially excluded and 
involved in drug distribution as a method of income generation  
 
the implementation and analysis of the results of ethnic monitoring.  
 
Given the link between drug use and social exclusion, drug policy development 
should include connections with other health, social, and regeneration agendas. 
 
Evaluation should be a key component of all drug services for BME groups and an 
EU-wide database of such initiatives should be constructed to ensure that lessons 
can be learned from them.  Given the gaps in the knowledge base on the drug use 
of, and related service provision for, BME groups, research results and examples of 
good practice amongst drug services should be widely disseminated. 
 
The current study was only the very first step in constructing an overview of the drug 
use of BME groups in the EU.  A highly fruitful next step would be to use the Delphi 
method:  to devise just one questionnaire based on a synthesis of the results from 
this study and repeat the exercise, increasing the range and diversity of informants, 
and including strategies that encourage the participation of more BME groups in the 
data collection process.  
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We are very conscious that, within the European Union, various terms are used to 
refer to the many diverse communities living in the member states.  We prefer the 
term Black and minority ethnic (BME) groups / communities.  This reflects that our 
concern is not only with those for whom 'Black' is a political term, denoting those who 
identify around a basis of skin colour distinction or who may face discrimination 
because of this or their culture:   'Black and minority ethnic' also acknowledges the 
diversity that exists within these communities, and includes a wider range of those 
who may not consider their identity to be ‘Black,’ but who nevertheless constitute a 
distinct ethnic group. 
 
Centre for Ethnicity and Health, University of Central Lancashire, Preston, UK 
 
 
 
1  Background to the project 
 
An EMCDDA project to map available information on the relationship between drugs 
and social exclusion was conducted from September 1999 - November 2000 
(Mapping available information on social exclusion and drugs, focusing on 'minorities' 
across 15 EU member states, Khan et al, 2000).  That project collected data mainly 
through the available literature and a network of 14 partners throughout the 
European Union (EU), and provided information on definitions of Black and minority 
ethnic (BME) groups;  socio-demographic and economic conditions of BME groups;  
the situation of these groups in terms of social exclusion and drug use;  national 
policies on drugs and BME groups;  and selected examples of relevant practice 
interventions.  
 
As a mapping exercise, the previous project did not allow a descriptive overview of 
drug use amongst BME groups in the EU, the consequences of this, nor an analysis 
of the hypotheses that might explain the differences observed between their drug use 
and that of the rest of the population.  Consequently, the current project was 
commissioned by EMCDDA to focus on patterns of drug use and their consequences 
and correlates amongst all BME groups in the EU.  The objective was to collect more 
comprehensive data to assist in answering the following questions: 
 
What is the situation regarding drug use amongst minorities (levels, trends, 
patterns, health, social and legal consequences, and correlates) and how 
does it compare to the general population? 
 
What information exists that might help account for any differences observed 
(eg  cultural traditions, including 'protective' ones, reporting differences, social 
exclusion, discrimination, etc)?   
 
This was an ambitious undertaking in the time (eight months) and financial resources 
allowed for the project, so the Centre for Ethnicity and Health aimed to fulfil the 
objectives by employing creative data collection methods.  Much of the drug use of 
BME communities is undocumented and ethnic monitoring is inconsistent and 
inadequate both within and between countries.  To overcome these significant 
barriers to data collection, the sources of information utilised by the previous project 
were considerably expanded, in order to provide a more comprehensive picture of 
drug use and related issues amongst BME communities in the EU.   In total, 1,122 
individuals or organisations throughout the EU were contacted for information. 
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Section 2 of this report describes and discusses the methods used to collect data for 
this study:  the identification of potential informants, the research instrument, the data 
collection process, the responses and response rate, and how the data were 
analysed.   
 
Section 3 presents a thematic synthesis of the data according to the broad themes 
of: 
 
the acknowledgement of drug use amongst BME communities and the value 
of ethnic monitoring 
 
prevalence of drug use amongst BME communities, including data from drug 
services and the criminal justice system 
 
patterns of drug use amongst BME communities, including cultural variations;  
factors specifically affecting their drug use;  the effects of social exclusion;  
myths, scapegoats and stereotypes;  and barriers to drug service access    
 
the research agenda, including the need to confront the hidden nature of drug 
use amongst BME communities;  to collect comparable data across the EU;  
to consider the researchers and informants who can best expand the 
knowledge base;  and to disseminate information 
 
drug service development, including example of good practice 
 
a summary of the findings and recommendations in the form of key points for 
consideration by policy-makers.    
 
The wide variety of publications, government reports, websites, etc. that informed the 
current project have been added to the relevant country profiles in Volume 2 and also 
appear in alphabetical order in Section 4 of Volume 1. 
 
Detailed profiles of the situation regarding the drug use of BME groups in each EU 
country and Norway are presented in Volume 2. 
 
This study did not reproduce the work conducted on EMCDDA's previous 
investigations into BME groups in the EU (Khan et al, 2000), but concentrated on 
drug use amongst them.  Although the relevant information from Khan et al was 
incorporated into the current study, comprehensive details of the socio-demographic 
and economic conditions of these groups, national drug policies, and some examples 
of practice interventions can be found in the report on the previous project. 
 
 
This report is a synthesis of the findings that are presented in the detailed country 
profiles in Volume 2.   Although it is not intended that any country profile is used as a 
‘stand-alone’ report of drug use amongst Black and minority ethnic communities, they 
contain a wealth of local and national information on drug use amongst BME groups. 
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2  Methods 
 
This section reports on the methods used to collect data on the drug use of BME 
groups in the EU.  It describes how potential informants were identified, how the 
research instrument was constructed, the process of collecting data, issues arising 
from the responses and the response rate, and the data analysis process. 
 
In order to obtain a descriptive overview of drug use amongst BME groups to fulfil the 
aims of this study, the research methods consisted of three major elements.  For 
each country: 
 
a list of potential informants was compiled from databases of individuals and 
organisations working in the drugs field and/or with Black and minority ethnic 
groups  
 
key messages were extracted from EMCDDA's previous work on this issue 
(Khan et al, 2000) and used to devise a questionnaire to ask respondents 
how accurate they thought they were, to add any other information they had 
(such as that from academic journal papers, research reports, the media, 
relevant websites, and from personal experience or rumours), and to provide 
contact details of other potential informants 
 
questionnaires were sent to any new informants suggested by respondents.  
 
 
2.1  Identification of potential informants 
 
The experience of the Centre for Ethnicity and Health from our work in the UK, and 
from information from the previous project (Khan et al, 2000), is that much of the drug 
use of BME communities is undocumented and that ethnic monitoring is unlikely to 
be consistent and adequate both within and between EU countries.  To overcome 
these significant barriers to data collection, the 'one partner per country' method used 
by the previous project was considerably expanded, in order to provide a more 
comprehensive picture of drug use and related issues amongst BME communities in 
the EU.  The Centre's work in the UK has established that the identification of 'key 
players,' from a range of disciplines, is an extremely productive method of obtaining a 
descriptive overview in the absence of statistical information (it was clear from the 
previous project that it is not possible to obtain prevalence rates of the drug use of 
BME communities).   
    
Potential informants were identified and contacted on an on-going basis throughout 
the project, from the following sources: 
 
the Centre for Ethnicity and Health's database of contacts that includes a 
wide variety of BME forums and the Centre's international and European 
contacts 
 
contacts from EMCDDA's previous work on the drug use of BME groups in 
the EU (Khan et al, 2000) 
 
QED (network of qualitative drugs researchers in the EU - 
http://www.qed.emcdda.org)  
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UNDCP Directory of non-governmental organizations working in drug demand 
reduction, 2001 
 
EMCDDA's Annual Report 2001 
 
the REITOX National Focal Points' 2001 annual reports to EMCDDA 
 
via the project manager at EMCDDA, 15 REITOX National Focal Points 
(NFPs) in the EU were asked to participate in the project as a voluntary task 
 
relevant conference participant lists 
 
a flyer inserted in the conference bag at the International Conference on the 
Reduction of Drug Related Harm, Ljubljana, Slovenia, in March 2002  
 
requests for contacts on several relevant electronic discussion lists, in the 
UK's DrugScope Members' Briefing and EMCDDA's Drugnet Europe, on 
EMCDDA's QED website, and by email to all the qualitative drug researchers 
listed in QED's Directory of Researchers 
 
EMCDDA staff, via the project manager at EMCDDA 
 
relevant websites and databases concerned with drug use and/or BME 
groups as follows: 
 
 
 
A-Clinic Foundation  AC Company - European Project for the 
Target Group of Mobile Drug Users 
ARCHIDO Council of Europe, Pompidou Group 
DrugScope (UK) Exchange on Drug Demand Reduction 
Action (EDDRA) 
EURIDICE European Addiction Training Institute 
(EATI) 
European Association of Libraries and 
Information Services on Alcohol and 
Other Drugs (ELISAD) 
European Group for Exchange Rhine-
Meuse-Moselle (GEERM) 
European Cities on Drug Policy (ECDP) European Commission 
European Household Survey Panel Euro-methwork 
European Network for Practical 
Approaches in Addiction Prevention  
(EURONET) 
European Network for Prevention of Drug 
Abuse - Drugs and Images Network 
Hamburgische Landesstelle gegen die 
Suchtgefaren - Three Cities Project 
European Network of Drug and HIV/AIDS 
Services in Prison  
European Network of Telephone Drug 
Helplines (FESAT) 
European Network on Drug Abuse 
Prevention among Children and Young 
People (DAP)  
European NGO Council on Drugs and 
Development (ENCOD) 
European Society for Social Drug 
Research (ESSD) 
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European Society of Professionals 
Working with Drug Dependencies  
(ITACA) 
Federation of European Professionals 
Working in the Field of Drug Abuse 
(ERIT) 
Forum Européen Pour la Sécurité 
Urbaine 
Fundación Secretariado General Gitano  
/ European Network for Drug Abuse and 
HIV/AIDS Prevention in the Romany 
Community (FSGG / SASTIPEN) 
Gruppo Abele Hassela Nordic Network 
International Council on Alcohol and 
Addictions (ICAA) 
INSUFO  
International Parenthood - Drug Abuse 
Network (RIPUDD) 
IREFREA (promotion and research of 
prevention of drug and other child and 
adolescent problems) 
Les Étrangers en France (INSEE) Le Système Français de Prévention et de 
Soins en Toxicomanie (ANIT) 
Medecins Sans Frontieres National Acupuncture Detoxification 
Association (NADA) 
OCRIS Odense Kommune (ROPLNZ) 
TMC c/o PRAXIS (working with drug 
users in prison) 
Toxicomanies - Europe - Echanges - 
Etudes (T3E) 
Trimbos Institute - Trimbos Peer Support 
Project 
United Nations International Drug Control 
Programme (UNDCP) 
United Nations High Commission for 
Refugees (UNHCR) 
 
 
 
In addition to all of the above, the list of potential informants grew as more were 
provided in completed questionnaires. 
 
 
2.2  Research instrument 
 
The research instrument designed for this project was a series of questionnaires - 
different for each country - compiled from relevant key data from EMCDDA's previous 
investigations into the drug use of BME groups in the EU.  For each country, the 
information from Khan et al (2000) was collated in the form of statements about each 
BME group, with which respondents were asked to indicate their level of agreement. 
For example, Khan et al report that in Spain, Gypsies who use drugs do not access 
drug services.  The questionnaire for Spain therefore included a statement 'Gypsies 
who use drugs do not access drug services' and asked respondents to indicate their 
level of agreement using a 5-point scale (strongly disagree - strongly agree).  
Respondents were also asked for any other information about each BME group, for 
general information about all BME groups, whether any groups were missing from 
the list in the questionnaire, for details of relevant publications and other documents, 
and for the contact details of others who may be able to provide information for the 
study.  An example of a questionnaire appears in Appendix 1.   
 
A letter (Appendix 2) accompanied the questionnaire, and explained the background 
to the project.  Letters were personally addressed to potential respondents (ie  Dear 
name).  The questionnaires and accompanying letters were translated by a 
professional translating service into the main language for each country (two 
languages in the case of Belgium). 
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In order that potential informants were not discouraged from responding because 
they thought they had too little information, both the questionnaire and the 
accompanying letter stressed that:   
 
We don't expect anyone to be able to answer all the questions!  However, 
even if you only have one small piece of information, please take a few 
moments to add it to the questionnaire.   Not much is known about this issue, 
so anything you can tell us will be valuable. 
 
This study was already underway when the Centre for Ethnicity and Health began to 
develop links with the Norwegian Temperance Alliance around BME community 
engagement issues, and the Alliance volunteered to participate, providing the contact 
details of others who could also help.  Norway is not a member of the EU and was 
therefore not included in the study by Khan et al (2000).  Unlike other EU countries, a 
questionnaire on the drug use of BME groups in Norway asking for levels of 
agreement with series of statements could therefore not be compiled.  Instead, 
contacts were given a list of general questions on this issue. 
 
 
2.3  Data collection 
 
The questionnaire and accompanying letter were sent to 1,122 potential informants in 
both English and their native language, with a request to answer in English if 
possible. The strategy of providing the questionnaire and letter in potential 
respondents' own language proved to be successful, and is doubtless responsible for 
the overall high response rate (see Section 2.4):  the large proportion of responses 
that were not in English indicates that these would not have been forthcoming if the 
questionnaire had been sent in English only.   
 
The strategy to identify informants had produced a somewhat bewildering array of 
European organisations concerned with drugs and/or BME groups, and revealed that 
some are connected to each other, the same individuals are involved in several 
different organisations, and, unfortunately, that many contact details (particularly 
email addresses) on databases are out-of-date.  Time-consuming aspects of the data 
collection period included trying to locate specific individuals and organisations who it 
was thought could provide valuable information to the study, but for whom the 
available contact details were incorrect. 
 
Another resource-consuming aspect of the project was dealing with the volume of 
information that was received in addition to responses on the questionnaire.  Whilst 
this was extremely welcome, resources did not allow for a verbatim translation of the 
large amount of material that was in a language other than English.  Using the 
research team's colleagues and friends who understood the relevant languages, and 
the internet translation wesbite http://www.babelfish.altavista.com, the information 
was summarised, checked for relevancy to this study, and, if appropriate, added to 
the relevant sections of the questionnaire to facilitate a coherent analysis of all the 
data collected for this study. 
 
Data collection continued for four months, from the end of February to the end of 
June, 2002.  All contacts and responses were recorded on a specially-designed 
contact monitoring form, and reminders sent to those who had not responded after 
four - six weeks.  Wherever possible, informants were contacted by email, although if 
they did not respond to this, reminders were sent as hard copies by ordinary mail. 
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2.4  Responses 
 
Table 1 shows that the questionnaire and accompanying letter were sent to 1,122 
potential informants, and that the overall response rate was 28.7% or 1 in 3.5, an 
extremely high rate for a postal / email survey.  The response rate varied 
considerably however, from 12.5% (Netherlands) to 71.1% (Finland):  each country's 
response rate is discussed in the Country Profiles in Volume 2.   
 
The reasons some of those contacted to participate in this study did not respond at 
all, even to decline the invitation, can only be speculated.  It could be that in some 
countries, a response to say 'I have no information' or 'I do not want to participate 
because ...' is thought unnecessary.  No such responses were received from Greece, 
Norway, and Portugal.  In Sweden, on the other hand, responses of this nature 
outnumbered those with information.  Nonetheless, overall, almost three-quarters of 
responses - a total of 239 - contained information.     
 
 
2.4.1  Responses with no information 
 
Responses stating that the sender had no information were an aspect of this study 
that merits consideration alongside the findings and when further work on the issue 
of drug use amongst BME groups is conducted.  Responses with no information fell 
mainly into one of three categories: 
 
• Those who simply said they had no information - the largest proportion.  In 
the case of France, this was frequently followed by the comment that 
under French legislation, ethnic monitoring cannot be conducted.   
 
• Those who misunderstood the aim of the project and the origin of the 
statements in the questionnaire, despite the explanation in the 
accompanying letter.  For example, it came to the attention of the research 
team that some of the drug professionals contacted in Austria feared that 
the results of this study would further stigmatise BME groups there by 
increasing racism and nationalism;  and that some Belgian drugs 
researchers who had received the questionnaire had circulated an email 
urging others not to respond because they saw the survey as a tool to 
stigmatise BME drug users, and were concerned about implications of the 
results in terms of immigration policy.  In Austria, complaints became so 
vehement that, after discussions with EMCDDA and the Austrian REITOX 
National Focal Point, data collection was prematurely halted in that 
country.  In Belgium, a respected drugs researcher intervened on behalf of 
the research team and contacted complainants in their own language to 
attempt to allay their fears.   
 
This reaction is surprising in the sense that it was thought (albeit by a small 
minority of those contacted) that EMCDDA and the Centre for Ethnicity and 
Health may use the results of the study in a way that would impact 
negatively on BME groups in the EU.  On the other hand, the reaction was 
not entirely unexpected, as the Centre's experiences in the UK have 
revealed that it is difficult for many individuals and organisations (including 
policy-makers, drug researchers, drug service planners and  
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commissioners, and BME groups themselves) to acknowledge that there is 
problematic drug use amongst BME groups, because they fear 
accusations of racism and want to avoid increasing stigmatisation of these 
communities.  This issue is further discussed in Section 3.1.  
 
Other comments questioning the validity and ethicality of the method of 
data collection and declining to give an opinion not based on 'objective 
facts' were made directly to the research team by recipients of the 
questionnaire from Belgium (by 2 respondents), Denmark (4), Spain (2), 
Sweden (4) and the UK (2).   
 
• The third group of those who did not provide information were those who 
gave another reason for not doing so.  For instance, two youth workers 
from Austria said that they could not provide any information because they 
did not have any drug users amongst their clients, and a respondent from 
France because they no longer work in the drugs field.  However, it is 
believed that such respondents had misunderstood that information was 
not only required from 'drug experts,' but from a wide range of those who 
come into contact with BME groups.    
 
 
2.4.2  Terminology 
 
As discussed earlier, the Centre for Ethnicity and Health prefers to use the term 
'Black and minority ethnic groups,'  although in the questionnaire for this project, we 
felt that 'minority ethnic' or 'ethnic minority' would be most easily understood by 
potential informants.  In the previous project, Khan et al (2000) devoted considerable 
effort to categorising the different BME groups in each EU country.  However, given 
that the questionnaire for the current study had separate sections, each headed with 
the name of the group in question (Pakistani, Iranian, Central and Eastern European, 
Black African, Gypsy / Roma, etc), it was felt that it was clear about which groups 
questions were being asked, whether or not they were regarded as a BME group by 
a particular country and/or respondent.  The terminology did not appear to affect 
responses, despite being unfamiliar to some respondents. 
 
Nevertheless, a few respondents - from Denmark, Finland, France, Germany, and 
Greece - commented on the term 'minority ethnic groups.'  For example, it was 
pointed out that, in Greece, the only officially-recognised ethnic minority is the 
'Muslim minority' and it is clear from Khan et al (2000) that some BME groups - such 
as Gypsies in Portugal and Spain - are officially categorised as Portuguese and 
Spanish citizens.  
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Table 1:  Contacts and response rate 
 
 RESPONSES WITH 
INFORMATION 
 
 
CONTACTED 
N 
 
RESPONSES 
N 
 
RESPONSE 
RATE N OF ALL 
RESPONSES 
AUSTRIA 78 20 25.6% 14 70.0% 
BELGIUM 72 22 30.6% 14 63.6% 
DENMARK 40 13 32.5% 9 69.2% 
FINLAND 45 32 71.1% 28 87.5% 
FRANCE 99 24 24.2% 19 79.2% 
GERMANY 104 21 20.2% 15 71.4% 
GREECE 35 7 20.0% 7 100% 
IRELAND 77 15 19.5% 11 73.3% 
ITALY 58 14 24.1% 11 78.6% 
LUXEMBOURG 19 8 42.1% 6 75.0% 
NETHERLANDS 80 10 12.5% 5 50% 
NORWAY 8 5 62.5% 5 100% 
PORTUGAL 47 12 25.5% 12 100% 
SPAIN 125 32 25.6% 25 78.1% 
SWEDEN 50 20 40.0% 9 45.0% 
UK 185 67 36.2% 49 73.1% 
 
 
TOTAL QUESTIONNAIRES SENT        
 
TOTAL RESPONSES                                
 
OVERALL RESPONSE RATE                
  
 
RESPONSES WITH INFORMATION         
 
OVERALL PROPORTION OF 
RESPONSES WITH INFORMATION            
                                                                  
 
 
1,122 
 
322* 
 
at least* 28.7%  /  1 in 3.5 
range 12.5% - 71.1% 
 
239 
 
74.2%  /  1 in 1.3 
range 45% - 100% 
 
 
 
*In some cases, questionnaires were sent to several members of the same organisation, 
but there was just one response on behalf of the whole organisation.   
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2.4.3  Response to the request for further contacts 
 
Informants to this study gave a total of 302 contact details of individuals and 
organisations they thought could provide further information.  All those who were not 
already on the project's database were sent a questionnaire.  Informants from Spain, 
Italy and Portugal gave the largest number of further contacts (56, 53 and 40 
respectively).   The least number of new contacts were from Denmark (3), Norway 
(4), Belgium (7), Luxembourg (8 - although this is a relatively small country), the 
Netherlands (8), and Sweden (8).  
 
As discussed in Section 2.1, the method used to collect data for this project moved 
far beyond the traditional interpretation of 'research partners.'  For the 'key player' 
method to be most productive, however, informants should not be restricted to those 
working in the drugs field and academics, as the Centre's previous work has shown 
that those involved in other aspects in the health and welfare of BME communities 
are also likely to have information about drug use amongst these communities:  as 
diverse a range of informants as possible was crucial to the compilation of a valid 
overview of the drug use of BME groups in the EU.  This was clearly explained in the 
questionnaire as follows: 
 
Please give the names and contact details (address, telephone, fax, email, 
website) of any person or organisation you think could give us more 
information.   We will then send this questionnaire to them, or, if you prefer, 
you can copy it and the accompanying letter and send it to them yourself.  
Note that contacts need not be working in the drugs field as, for example, 
researchers or drug service providers.  Valuable information can also be 
provided by ethnic minority community organisations, general health and 
social services, social workers, the police, regional and local government 
services, youth services, etc. 
 
Table 2 shows the occupations of respondents to this study, revealing that one-third 
(104/32%) were from drug research organisations or universities, and 29% (93) were 
from drug services.  The first phase of the identification of potential informants 
detailed in Section 2.1 was concentrated heavily on drug researchers and drug 
services, but it was hoped that information on completed questionnaires would lead 
to contacts from other disciplines.  Although this aim was achieved, and this study 
has laid the foundations for future work using the key player method in the EU, few 
drug researchers and drug service workers gave contacts outside their own 
professional network.  In particular, few gave contacts of BME organisations other 
than large, national organisations such as Fundación Secretariado General Gitano in 
Spain.  Although 29 responses to this study were received from BME organisations, 
20 were from the UK, from the Centre for Ethnicity and Health's own database. 
Nevertheless, 39% (125) of all respondents were neither from drug services nor 
research organisations / universities, showing the value of the strategy of asking for 
information from outside these disciplines.   
 
Although a few informants provided lists of BME community organisations in their 
countries, these contained many outdated or incomplete contact details.  For 
example, many questionnaires sent to those on a database of 351 BME 
organisations given to the study by an informant in Finland were returned to the 
research team marked 'moved premises' or 'address not recognised,'  and the list 
was received too late in the data collection period to investigate the whereabouts of 
those whose contact details were incorrect.  Another example is a list of BME 
organisations received from a Greek informant:  in some cases, no postal nor email 
address was given, meaning that a questionnaire could not be sent to them.      
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Table 2:  Occupations of respondents 
 
Occupation total Aus Bel Den Fin Fra Ger Gre Ire It Lux Neth Nor Por Sp Swe UK 
Research / 
university 
104 4 12 9 7 11 3 1 5 4 3 4 2 1 12 10 16 
Drug service 93 5 3 2 15 5 14 2 5 6 3  3 4 10 3 13 
BME 
organisation 
29*    2*    2     1 4  20 
Government 
department / 
drug policy 
21 4 1 1 1    1 3  2   3 1 4 
European / 
international 
organisation 
17  3   2 1   1  2   1 6 1 
Social worker / 
community 
worker 
11 3   1   2 1     3   1 
Health service 10      2     1     7 
Youth worker / 
teacher 
5 3       1  1       
Journalist / 
media 
3    1 2            
Librarian 3     2         1   
Prisons 2  2               
Police 2    2             
Immigration 1    1             
Cultural 
planning officer 
1    1             
REITOX 
National Focal 
Point 
7 1  1  1  1   1 1 Not 
appli-
cable 
 1   
Unknown 13  1  1 1 1 1      3   5 
TOTAL 322 20 22 13 32 24 21 7 15 14 8 10 5 12 32 20 67 
*This statistic excludes responses to a mailshot to 351 BME community organisations on an database provided by an informant:  these 
questionnaires were sent at the very end of the data collection period, and, at the time of writing, have attracted only 5 responses, 3 of which had no 
information.  The database may be outdated, as many questionnaires were returned marked 'moved premises' or 'address not recognised.'  
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2.5  Data analysis 
 
As shown in table 3, of the total of 239 individuals and organisations who sent 
information to this study, 157 completed the questionnaire.  Many of these 
respondents not only gave additional information where requested on the 
questionnaire, but also sent it in other forms, such as research reports, journal 
papers, statistics on drug treatment clients and drug law offences, and the results of 
literature and other database searches.  Over one-third (82/34.3%) of informants did 
not complete the questionnaire, but provided information in another form. 
 
 
Table 3:   Questionnaires and other information received 
 
 Completed 
questionnaire 
Other 
information 
Total 
AUSTRIA 10 4 14 
BELGIUM 8 6 14 
DENMARK 5 4 9 
FINLAND 18 10 28 
FRANCE 3 16 19 
GERMANY 9 6 15 
GREECE 4 3 7 
IRELAND 7 4 11 
ITALY 8 3 11 
LUXEMBOURG 4 2 6 
NETHERLANDS 4 1 5 
NORWAY 4 1 5 
PORTUGAL 10 2 12 
SPAIN 17 8 25 
SWEDEN 2 7 9 
UK 44 5 49 
TOTALS 157 82 239 
 
 
Factors influencing the data analysis methods employed by this project were: 
 
• The statements on the drug use of BME groups in each country were based on 
EMCDDA's previous work on this issue (Khan et al, 2000).  As the information 
provided by Khan et al was different for each country, the statements in each 
country's questionnaire were also different and could not therefore be collated 
and compared across the EU. 
 
• The sources of data varied between countries.  For example, much of the 
information on the drug use of BME groups in Sweden was from research that 
was conducted between 1991 and 1995, whilst that from Norway was based on 
current research;  drug treatment and/or drug law offence statistics figured 
largely in the information from Austria, Denmark, Ireland, Italy, and 
Luxembourg, whilst information received from Finland indicated a strong 
qualitative knowledge base.  Ethnic monitoring cannot legally be conducted in 
France and appears not to be conducted in Belgium, Greece, Portugal, and 
Spain, so the information from these countries was largely of a qualitative 
nature. 
 26
 
The data from informants were collated as profiles for each of the 16 participating 
countries (Volume 2).  Clearly, the variety of forms in which information was received 
meant that a statistical analysis was highly unsuitable.  Consequently, a thematic 
analysis was then performed on the data, according to themes that most consistently 
arose and that are pertinent to the drug use and related issues of BME groups on 
local, national and EU-wide levels.  These themes are therefore firmly grounded in 
the data received from informants during this study. 
  
The results of this analysis appear in the following section.     
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3  Overview of the drug situation amongst Black and minority 
ethnic groups in the European Union 
 
 
 
The information on specific BME groups and countries reported in this section are 
derived from that collected for the study and do not necessarily represent the views 
of the authors of this report.  Further details of all the illustrations given below can be 
found in the relevant country profiles in Volume 2. 
 
The variations in this information, discussed at the beginning of this section, should 
be firmly borne in mind throughout.   
 
 
 
This section presents a thematic synthesis of the data according to the broad themes 
identified by this study.  As shown in detail in Section 2, the amount of data collected 
varied tremendously between countries.  There were also variations in the  aspects 
of the drug use of BME groups in the information received for each country, not least 
because each questionnaire was compiled from information provided by EMCDDA's 
previous work on this issue (Khan et al, 2000):  it is to be expected that, given the 
gaps in the knowledge base, the type of information reported in Khan et al was not 
consistent across all countries.  Because of these variations, no attempt has been 
made to collate and compare the data to provide a picture of the drug use of a 
specific BME group across the whole of the EU, nor to compare drug use between 
specific BME groups.  Such an exercise would indicate, for example, that in all the 
countries in which a particular BME population are living, there is use of a particular 
drug amongst them, but this would generate an extremely distorted picture of the 
situation.   
 
Examples of variations in the information received include the following: 
 
Whilst 29 (66%) of the 44 respondents who completed the UK questionnaire 
agreed that there is heroin use amongst people from India, only one informant 
from Germany had any information on the drug use of this group. 
 
The information from France and Norway was largely based on qualitative 
research investigations amongst drug users not in treatment, whilst 
informants from Austria, Denmark, Ireland, Italy, and Luxembourg tended to 
report drug treatment and/or drug law offence statistics. 
 
In some countries, although valuable information was obtained about the drug 
use of a particular BME group, it was sometimes restricted to a particular 
locality, and may or may not be representative of the situation in the whole 
country, or of drug use amongst the whole BME population in question.  
Examples of this are reports on the drug use amongst Maghrebians in 
Provence Alpes Côte d'Azur in France, and amongst BME groups who 
frequent the drug-using street scene in Oslo, Norway.    
  
In some cases, there was a lack of consensus on a particular issue amongst 
informants from the same country, such as whether or not there are drug 
services in Greece that target BME drug users;   if North Africans in Italy are 
more involved in drug law offences than other BME groups;  and if Gypsies in 
Portugal are under-represented in drug services. 
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The BME communities in each country also vary according to past and 
current migration patterns (fully described in Khan et al, 2000):  for example, 
whilst the largest BME group is the UK is from South Asia (Bangladesh, India 
and Pakistan), South Asians do not appear to live in Greece;  Gypsies are the 
largest BME group in Spain but were not reported from Sweden;  and whilst 
Moroccans are the largest BME group in Italy, there do not appear to be any 
of these North Africans in Denmark. 
 
Given the above variations, in order to provide an overview of the drug situation 
amongst BME groups in the EU, a thematic analysis was performed according to 
issues which most consistently arose via the information collected by this study.  
The themes are therefore firmly grounded in this information, and throughout this 
analysis, examples extracted and used as illustrations.           
 
The themes discussed in this section are: 
 
the acknowledgement of drug use amongst BME communities and the value 
of ethnic monitoring 
 
the prevalence of drug use amongst BME communities, including data from 
drug services and the criminal justice system 
 
patterns of drug use amongst BME communities, including cultural variations;  
factors specifically affecting drug use amongst BME groups;  the effects of 
social exclusion;  myths, scapegoats and stereotypes;  and barriers to drug 
service access    
 
the research agenda, including the need to confront the hidden nature of drug 
use amongst BME communities;  to collect comparable data across the EU;  
to consider the researchers and informants who can best expand the 
knowledge base;  and to disseminate information 
 
drug service development, including examples of good practice. 
 
Finally, a summary of the findings and recommendations is provided in the form of 
key points for consideration by policy-makers. 
 
 
 
3.1  Acknowledgement of drug use amongst Black and minority ethnic 
communities 
 
This section discusses the effects on the knowledge base of the failure to 
acknowledge drug use amongst BME groups and the lack of ethnic monitoring.     
  
It is clear from some of the responses received by this study that, in several EU 
countries, drug use amongst BME communities is unacknowledged, ignored, 
unrecognised, or hidden by some policy-makers, drug researchers, drug service 
planners and commissioners, and by some members of some BME groups 
themselves.  The study revealed many examples to illustrate this.  For instance: 
 
Policy-makers in Germany, the Netherlands, Spain, and Sweden are failing to 
address drug use amongst BME groups.   
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As discussed in Section 2.4.1, some of those involved in the drugs field in 
Austria and Belgium refused to participate in this study because of fears of 
increasing racism, nationalism, and stigmatisation of BME groups. 
 
With a few exceptions, such as research amongst Gypsies in Spain and 
South Asians in the UK, this study was characterised by a lack of 
investigation into drug use amongst BME communities and the surrounding 
issues.  There are a variety of reasons for this, including the avoidance of 
further stigmatisation of these groups, fears of accusations of racism by 
exposing drug use amongst them, lack of access to the communities in 
question, and language barriers.  The UK probably has the widest knowledge 
base, but even so, large gaps in it remain. 
 
Some BME communities and families hide drug use within them for a variety 
of reasons, including to avoid the stigma associated with drug use by their 
community and a fear of being ostracised.  Therefore, many BME families 
and/or communities reject drug users completely, such as the Turkish 
community in Austria, Finland, and the Netherlands;  the Gypsy / Roma 
community in Finland and Spain;  and some BME groups in the UK, 
especially South Asians.  In the UK, another method of hiding drug use within 
the South Asian communities is for the drug user's family to either attempt an 
enforced 'home detoxification' or to send the drug user 'home' to Bangladesh, 
India, or Pakistan in the hope that they will 'recover.'  However, due to the 
availability and cheapness of drugs in these countries, some return with a 
greater dependence. 
  
The reluctance to acknowledge drug use amongst BME groups in order to avoid 
further stigmatisation is misguided.  Ignoring or hiding a problem does not make it 
disappear:  it must be confronted in order that appropriate responses can be 
developed.  Many BME groups are already stigmatised as drug users or dealers, yet 
refusing to accept that this behaviour may occur amongst them does nothing to 
decrease the stigmatisation, and obstructs consideration of their drug service needs 
by policy-makers and service planners and commissioners.    
 
 
 
3.1.1  Ethnic monitoring 
 
EMCDDA's previous work on the drug use of BME groups (Khan et al, 2000) 
discusses the issue of ethnic monitoring in some detail, particularly in relation to how 
categories are devised, how ethnic monitoring is implemented, and how the results 
are subsequently used.  That discussion will not be reproduced here, other than to 
emphasise that consistent, co-ordinated ethnic monitoring, based on a common set 
of classifications, is a reliable instrument to measure drug service use and, 
importantly, non-use, by drug users.  Analysis of results of ethnic monitoring from 
drug services and drug surveys provide a baseline for improvements to the quality of 
service provision -  including equal access for all drug users and more equitable 
allocation of resources - and can be used to track changes in drug-using patterns 
and in the uptake of drug services. 
 
Ethnic monitoring is an extremely sensitive issue, especially when drug use is being 
monitored, and there was a great deal of variation in the approach to this from the 
countries participating in this study.  Although this study's questionnaire did not 
specifically ask about this topic, it was raised by some informants from every country: 
 30
In Austria and Portugal, ethnic monitoring is not conducted except, it appears, 
by the criminal justice system.  However, in Austria, crime statistics do not 
show ethnicity, but nationality, and some BME groups, such as Roma / Sinti  
therefore appear as 'Austrians' or another nationality.  Nationality is also used 
to categorise populations in Belgium, Ireland (although Travellers are 
recorded as such), and Sweden.  
 
In Greece, the only officially-recognised BME group is the 'Muslim minority' 
comprising largely of Turkish people, but also Pomaki and Gypsies. 
 
Under French legislation, ethnic monitoring cannot be conducted in France. 
 
Ethnic monitoring does not appear to be conducted in Belgium and Germany. 
 
Some ethnic monitoring of drug service users is conducted in Denmark, 
Finland, Italy, Luxembourg, the Netherlands, and Norway and is widespread 
in the UK.  
 
Ethnic monitoring of drug service clients, hospital admissions relating to drug 
use, and drug overdose deaths will begin in Spain in 2003.  
 
However, although there is some form of ethnic monitoring of drug service clients 
and drug survey participants in the majority of EU countries, vast improvements are 
required to ensure more consistent data collection and analysis.  From the UK, where 
ethnic monitoring is conducted more comprehensively than in other EU countries, 
Sangster et al (2002:59) recommend improvements be facilitated by the following 
actions: 
 
'Funding the production of clear guidelines to ensure ethnic monitoring is 
consistent, co-ordinated and based on official classifications 
 
Ensuring that the benefits of monitoring are clearly felt by those involved in 
data collection.  This may involve training for frontline workers which focuses 
on the way in which monitoring can help to improve services.  It may also 
require improved systems by which results of monitoring are fed back to 
agencies. 
 
Increasing the capacity of DATs [Drug Action Teams in England that co-
ordinate the delivery of the national drugs strategy and act as a focus for joint 
planning by local agencies], to make use of statistical data and other research 
in planning and commissioning services. 
 
Monitoring referral and treatment outcomes for Black and minority ethnic drug 
offenders. 
 
Systems for improved data collection should include a particular focus on 
drug use among Black and minority ethnic women and girls.' 
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3.2  Patterns of drug use amongst Black and minority ethnic groups 
 
This section discusses what was reported to the study on the prevalence and 
patterns of drug use amongst BME communities, including cultural variations;  factors 
specifically affecting drug use amongst BME groups;  the effects of social exclusion;  
myths, scapegoats and stereotypes;  and barriers to drug service access. 
  
 
3.2.1  Prevalence of drug use amongst Black and minority ethnic groups 
 
Successive annual reports from EMCDDA on the state of the drugs problem in the 
European Union show that, other than for cannabis, the use of which is relatively 
common and not highly stigmatised, 'prevalence data are less reliable for more 
hidden patterns of use, such as heroin injection' (EMCDDA, 2000:11).  It follows that, 
as will be shown throughout this section, because drug use by some BME groups is 
extremely hidden, and because of the lack of research on this issue, the prevalence 
of drug use amongst these groups is even more difficult to assess.  It was clear from 
EMCDDA's previous work on this issue (Khan et al, 2000) that it is not possible to 
obtain prevalence rates of the drug use of BME communities, and the current project 
confirms the reasons for this.  
 
  
3.2.2  Data from drug services and the criminal justice system 
 
Much of the information on the drug use of BME groups received by this study from 
Denmark, Ireland, Italy, Luxembourg, and Sweden consisted of data from drug 
treatment statistics, and in Austria, Denmark and Spain drug law offence statistics 
were a major source of informants' knowledge.  Such data alone can therefore give 
an extremely distorted picture of the prevalence of drug use and of drug-using 
patterns, as they do not take into account those drug users who do not use drug 
services nor come to the attention of the criminal justice system.  Examples of how 
statistics exaggerate or understate the involvement of BME groups in drug use 
and/or distribution include:  
 
Black Africans in Austria, who are highly visible because of their skin colour, 
are associated with drugs by both the police and general public, fuelled by 
adverse media reports (Eisenbach-Stangl, 2002).   The consequence is that 
this group are over-represented in reports of drug crimes to the police, in 
statistics on recorded drug offences, and in charges for drugs offences.  In 
addition, after coming to the attention of the police, Black Africans are 
proportionally more likely than the rest of the population to be charged for 
drug distribution than for possession of drugs.  In Austria, although ethnic 
monitoring is not conducted by agencies other than the criminal justice 
system, it is recognised that BME groups are under-represented in clients of 
drug services. 
 
BME groups are under-represented in drug treatment client statistics in 
Norway, but over-represented in the drug law offence statistics.  There are 
indications that those described by one informant as ‘non-Western 
immigrants’ are targeted by the Norwegian police as suspected drug law 
offenders. 
 
Very few drug users from BME groups use drug services in Finland, despite 
evidence that there is drug use amongst these populations. 
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BME groups in Luxembourg are under-represented as drug treatment clients, 
apart from those from some other European Union countries especially from 
Portugal.  
 
The National Drugmonitor in the Netherlands shows that BME groups are 
under-represented in both drug inpatient and outpatient treatment services. 
 
In the UK, BME groups are under-represented in drug services and over-
represented in drug law offence statistics. 
 
  
3.2.3  Patterns of drug use 
 
The evidence collected by this study indicates that, although there are some cultural 
variations in the types of substances used and some risk factors specifically affecting 
drug use amongst BME groups, their drug-using patterns are not different from those 
of socially-excluded, white, indigenous populations.  However, to be successful, 
responses may have to be different, as discussed in detail in Section 3.4. 
 
As discussed in Section 3.1.1, ethnic monitoring of drug service clients would provide 
one indicator of patterns of problematic drug use amongst BME populations, but it is 
not conducted in all EU countries, and where it is, requires many improvements for 
this aim to be achieved.  A further illustration of the need for improvement comes 
from an informant of this study who is involved in the European Addiction Severity 
Index (EuropASI) project, which measures the dependency of clients in drug 
treatment from participating European countries.  This project could, theoretically, 
provide valuable data about BME drug users in treatment in the EU.  However, the 
informant reported that, although EuropASI screening includes detailed questions 
regarding land of birth, parents' land of birth, etc, these questions are not asked as 
often of BME groups as they are of the rest of the population because of 'language 
problems.'   The informant concluded that are therefore too few relevant EuropASI 
data to detect drug-using patterns for BME groups in general, or amongst specific 
populations. 
 
 
Cultural variations in the substances used by Black and minority ethnic drug users 
 
The cultural variations in the substances used by some BME drug users reported to 
this study include: 
 
The use of qat (or khat), appears to be restricted to members of the Somali 
community in Denmark, Finland, Italy, Norway, and Sweden. Some people 
from the Middle East, Somalia and Ethiopia use this drug in the UK and it is 
used amongst Black Africans in the Netherlands.  
 
'Marasotu' (literally grass from Maras, a town in south-west Turkey) is a 
powder that is held or chewed in the mouth for many hours, like qat, and used 
by some Greek and Turkish Cypriots in the UK.   
 
Amongst older Russians newly-arrived in Spain, pharmaceutical morphine 
and homemade opium preparations such as 'kompot' are used.   
 33
Opium is used amongst Iranians in Germany and people from the Middle East 
in the Netherlands. 
 
 
Factors specifically affecting drug use amongst Black and minority ethnic groups 
 
There are several factors exclusive to BME groups that may make them vulnerable to 
drug use:   
 
Some migrants have suffered trauma because of wars in their home 
countries.  This was noted amongst drug users amongst Central and Eastern 
Europeans in Austria and Denmark;  in Denmark amongst Pakistanis and 
people from the Middle East;  in the Netherlands amongst some BME groups;  
and in Sweden (although the research on this issue was conducted a decade 
ago) amongst Iranians, Lebanese, Africans, and South Americans.    
 
The immigration experience may not have lived up to expectations, which 
was noted amongst drug users from the former Yugoslavia in Denmark and 
North Africans in Spain.  
 
Some members of some BME groups were using drugs before they 
emigrated to an EU country and continued to do so once they arrived, 
although the substances used may change.  Examples include: 
 
Russians in Germany who used heroin in Russia and continued to do 
so after they left. 
 
Iranians who used opium in Iran but have changed to injecting heroin 
in Germany. 
 
Maghrebians who used cannabis only in North Africa, but changed to 
heroin in Italy. 
 
North African drug users in Spain, some of whom smoked cannabis in 
their home countries, but who began to smoke heroin and snort 
cocaine in Spain.   
 
An unwitting change of drug is reported amongst Turkish and Greek 
Cypriots in the UK, who used cannabis in Cyprus and were sold 
heroin as 'powdered cannabis' in the UK. 
 
That said, although some refugees and asylum seekers arrived in the UK with 
an established drug problem, drug use amongst some others did not start 
until they arrived in the country.  In the UK, this is particularly the case 
amongst the younger generations of South Asians, who have adopted the 
drug-using patterns of the white indigenous population.   
 
 
Drug use and social exclusion 
 
The focus of EMCDDA's previous work on BME groups (Khan et al, 2000) was social 
exclusion.  That project explored the relationship between BME groups, social 
exclusion, and drug use in depth, concluding (p9) that; 
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'Although the use and abuse of drugs is not restricted to any one sector of 
society, its high prevalence and associated social problems are particularly 
marked in areas and localities marked by social exclusion.  Minority [BME] 
drug users could therefore be said to be facing a position of double jeopardy:  
they carry the stigmata of racial exclusion and of drug use.'  
 
BME groups are vulnerable to problematic drug use in the same way as the socially-
excluded, white indigenous populations are, and this applies particularly to the 
younger generations of some groups.  It was pointed out by informants from most of 
the countries that participated in this study that drug use was more prevalent 
amongst the younger generations of BME groups than amongst the older 
generations, and many informants linked this with social exclusion.  This 
phenomenon was noted amongst: 
 
Turkish people and Central and Eastern Europeans in Austria 
 
people from Morocco, Greece, Italy, Portugal, Turkey and Spain in Belgium 
 
people from the former Yugoslavia and Turkey in Denmark 
 
Ingrians in Finland 
 
Tzigane / Gypises / Roma in France 
 
Turkish people in Germany 
 
Travellers in Ireland 
 
Moroccans and Antillians in the Netherlands 
  
BME groups who hang around the drug-using street scene in the Centre of 
Oslo, Norway 
 
Black Africans in Portugal, especially those from Cap Verde. 
 
Gypsies and some Africans in Spain. 
 
Pakistanis, Bangladeshis and African Caribbeans in the UK. 
 
This study did not aim to address drug distribution by members of BME groups in any 
detail, and the information available on this issue is reported in each country profile in 
Volume 2.  However, an aspect of social exclusion raised by this study was economic 
survival via involvement in the distribution of drugs.  This was noted amongst, for 
example, Black Africans in Austria, Antillians in the Netherlands, Cap Verdeans in 
Portugal, and Pakistanis and Bangladeshis in the UK.  Those employing this method 
of income generation are vulnerable to drug use, and their conspicuous wealth in 
impoverished communities makes selling drugs an attractive proposition to others.   
 
It was also suggested that involvement in drug distribution precedes drug use 
amongst, for example, Black Africans in Austria;  Antillians, Central and Eastern 
Europeans and Russians in the Netherlands;  and Gypsies in Spain.  
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That said, it was believed that some BME groups were selling drugs but that drug 
use amongst them was low.  These groups were Black Africans in Austria and 
Belgium, Asians in Belgium, people from the Middle East in Denmark, and Turkish 
people in the Netherlands.  
 
Another example of the link between poverty and drug distribution is that some Black 
Africans living in poverty in Africa have been recruited in their home countries to sell 
drugs in Austria and to smuggle drugs into Ireland. 
 
 
3.2.4  Myths, scapegoats and stereotypes 
 
In a discussion of using qualitative research to examine the nature of drug use 
amongst BME communities in the UK, Patel (2000:127) lists a series of statements 
collected from a range of Asian communities, including from religious 'leaders' and 
workers in statutory and non-governmental organisations in the drugs field.  These 
include: 
 
'Asian people don't use drugs.'  
 
'Religion prohibits drug taking - therefore it is not a problem.'  
 
'It [drug use] is a white western disease.'  
 
'Our strong religious and cultural values stop us from this behaviour.'   
 
Patel continues that 'These statements clearly highlight the dilemma facing agencies, 
researchers and drug workers in the UK, operating as a series of myths that have 
acted as barriers to the development and delivery of drug services for Asian minority 
ethnic groups.' 
 
The results of this study reveal that myths about the drug use of BME groups are not 
exclusive to the UK:  along with scapegoating and stereotyping, they are also 
apparent in other countries.  For example: 
 
The knowledge base on the involvement of members of BME groups in drug 
distribution is largely influenced by, and dependent upon, statistics from the 
criminal justice system, which can reflect a bias against BME groups (Section 
3.2.2);  media reports (which are often extremely biased, as noted in Austria 
and in Norway for example);  and impressions gained from the visibility of 
drug sellers on the street because of their skin colour, noted in Austria and 
Italy in relation to Black Africans.  However, Eisenbach-Stangl (2002) usefully 
unpacks the criminal statistics in Austria to show that there is little support for 
the 'Black skin, black market' stereotype of Black Africans as heroin dealers.   
 
Other examples of what may be stereotypical assumptions that are based on 
crime statistics include Albanians in Greece, who are blamed for the increase 
in the rise of heroin and cannabis use, especially by adolescents, because 
they sell these drugs cheaply;  and Antillians in the Netherlands who are 
thought to be 'heavily involved' in transporting drugs as 'drug mules' or 
'bodypackers.'    
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Some BME groups in the EU are described as 'close-knit' and that it is 
therefore 'difficult' for drug services to work with them because they 'do not 
allow interference from outside.'  This was applied to the Turkish population in  
Belgium and to Moluccans in the Netherlands, for instance.  However, as 
noted in relation to the Turkish community in Belgium, these difficulties can be 
equally translated as non-Turkish-speaking drug workers being unable to 
communicate with the Turkish community and drug services' lack of culturally-
appropriate responses.         
 
It is believed that 'strong social bonds' in some way protect BME groups from 
drug use.  This was reported in relation to BME groups in general in Austria, 
and to Turkish people in Germany. 
 
It is also believed that religion 'protects' some BME groups from drug use.  
This was suggested in relation to Iraqis in Finland, and as shown in the 
quotations from Patel (2000) earlier, to South Asians in the UK.  
 
The lack of research into the drug use of BME groups in the EU is reflected in the 
lack of consensus about their drug-using patterns compared to the rest of the 
population.  The results from this study suggest that, in some countries, the 'whiter' or 
more assimilated into the host country the BME group is, the more likely it is thought 
that their drug use would be the same as that of the white indigenous population.  
This was noted about, for example, northern European Union nationals in Belgium;  
the Swedish-Finnish population in Finland, whose drug use is thought to be 
'recreational' rather than problematic;  in Sweden, about the 'fully-integrated' South 
Americans and also the South Asians who were adopted by Swedish families in the 
1970s and 1980s;  and about other European Union nationals in Germany, Italy, 
Spain and Sweden.  On the other hand, it was suggested that drug use would 
increase amongst younger members of BME groups in Ireland as they became more 
assimilated, as has occurred amongst some BME groups in the UK;  and that 'giving 
up their Turkish traditions' has led to drug use amongst young Turkish people in 
Austria.  However, lack of integration into Dutch society was suggested as a risk 
factor for drug use by, for example, young Moroccan and Antillian males in the 
Netherlands. 
 
The lack of research into the drug use of BME groups throughout the EU also means 
that, currently, many myths, scapegoats and stereotypes can neither be confirmed 
nor demolished.  Even where research has demolished a particular myth, such as 
female Gypsies in Spain and South Asians in the UK do not use drugs, it persists.   
 
 
3.2.5  Barriers to drug service access by Black and minority ethnic groups 
 
The barriers to health and other services are a significant element of social exclusion, 
and in this study, these were explicitly or implicitly discussed by informants from 
almost every country in relation to the under-representation of BME groups as drug 
service clients.  The result of lack of access to drug services contributes to the 
hidden nature of drug use amongst some BME communities, and to the employment 
of alternative strategies to 'keep the drug use within the family / community' (Section 
3.1).       
 
The issue of barriers to drug services are thoroughly discussed in studies from the 
UK (Fountain et al, 2002;  Sangster et al, 2002) and the Netherlands Broers and 
Eland, 2000;  Van Wamel and Eland, 2001), and can be categorised as follows: 
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Lack of cultural sensitivity 
 
This was specifically noted as a reason for the lack of uptake of drug services by 
various BME groups in Belgium, Denmark, Germany, Greece, Ireland, the 
Netherlands, Norway, Portugal, Spain, Sweden and the UK.  An example is a lack of 
consideration of the significance of the family amongst some BME communities, and 
how drug users' families could be incorporated into drug treatment.  In the 
Netherlands, for instance, drug workers thought that the lack of including BME drug 
users' families in treatment programmes was one of the reasons for the high drop-out 
rate of BME clients;  and in Portugal, it has been discovered that Gypsy drug users 
are much more receptive to family, rather than individual, therapy.  Other examples 
of differing cultural sensitivities are that BME groups in Sweden attach stigma to 
seeking any help from social services, but especially for drug use;  and in the 
Netherlands, male drug users from BME some groups are ashamed to accept help 
from a female therapist.       
 
 
Ethnicity of drug service staff 
 
One of the components of a lack of cultural sensitivity is the ethnicity of drug service 
staff, and this was noted in the Netherlands, Norway and the UK.  However, in the 
UK, the ethnicity of drug workers has been shown to be a more complex issue than 
simply employing those who are from the same ethnic group as the clients the 
service is trying to attract (Fountain et al, 2002;  Sangster et al, 2002).  The 
complexities include that it should not be assumed that clients want to see a worker 
from their own ethnic background, as feelings of shame may thus be amplified;  and 
that one BME worker may be expected to be culturally-sensitive to the needs of 
every non-white client. 
 
 
Distrust of confidentiality 
 
A distrust of the confidentiality of drug services was given as reason for the under-
representation of BME drug users in drug services from Finland, the Netherlands and 
the UK.  This is a special problem for illegal immigrants who, obviously, do not want 
to come to the attention of 'official' institutions, as pointed out from Belgium, the 
Netherlands, and Spain.    
 
 
Language 
 
Language as a barrier to drug service access was noted in relation to the Turkish 
community in Belgium, Russians in Finland, Chinese people in Italy, and BME groups 
generally in the Netherlands and in the UK. 
 
 
Lack of knowledge about drugs 
 
The lack of knowledge about drugs - including a recognition of problematic drug use - 
was noted as a barrier to drug service access amongst some BME groups in the 
Netherlands, Spain, and the UK.  In the UK, a difference was noted between 
generations in some BME groups, with younger people having a far greater 
knowledge about drugs than the older generations. 
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Lack of awareness of drug services 
 
A lack of knowledge of the process of accessing drug services and what the services 
involve, was noted amongst BME groups generally in the Netherlands and the UK, 
and amongst Black Africans in Spain.  This lack of knowledge is not only a barrier to 
drug service access, but also leads to unrealistic expectations by those who do 
access services, and, as suggested from the Netherlands and Norway, a high drop-
out rate amongst BME clients.   
 
 
Stigma 
 
The failure of BME drug users and their families to admit to a drugs problem because 
of the associated shame was noted amongst the Roma / Sinti in Austria and 
Germany;  Moroccans and especially Turkish people in the Netherlands;  BME 
groups in Norway;  Gypsies in Portugal and (especially when the drug user is female) 
in Spain;  Iranian males in Sweden;  and amongst several BME groups in the UK.  
 
 
The failure of services to target BME drug users 
 
A solution to break down the barriers preventing BME communities accessing drug 
services (including not only treatment, but also education and prevention services) is 
to target them at specific BME groups.  In some countries, however, this is either 
constitutionally forbidden - for example, in France and in Portugal, or the issue of 
cultural diversity appears not to be addressed in relation to drug services - in 
Germany, the Netherlands, Spain, and Sweden, for example.  Nevertheless, as 
shown in Section 3.4.1 and in some of the country profiles in Volume 2, there are 
examples of good practice, including in those countries where targeted drug services 
are officially either not allowed or not encouraged. 
 
 
 
3.3  The research agenda 
 
This section discusses the considerations that should inform the research that is 
necessary to fill the gaps in the knowledge base about the drug use of BME groups 
at local, national and EU-wide levels.  The discussion covers the need to confront the 
hidden nature of drug use amongst BME communities;  to collect comparable data 
across the EU;  to consider the researchers and informants who can best expand the 
knowledge base;  and to disseminate information. 
  
 
3.3.1  Confronting denial 
 
As discussed in Section 3.1, denial that drug use is taking place amongst BME 
groups may have to be confronted, including amongst BME communities themselves.  
In a discussion of research of drug use amongst South Asian communities in the UK, 
Patel (2000:130) stresses that: 
 
'Researchers should be aware that they will encounter official bodies and 
professionals who will simply deny that Asian young people are as much at 
risk as the 'white' population;  researchers must be prepared to challenge 
those who dogmatically repeat these assumptions.' 
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It is necessary to repeat here that drug use amongst BME communities must be 
confronted in order that appropriate responses can be developed.  Many BME 
groups are already stigmatised as drug users or dealers, yet refusing to accept that 
this behaviour may occur amongst them does nothing to decrease the stigmatisation, 
and obstructs consideration of their drug service needs by policy-makers and service 
planners and commissioners. 
 
 
3.3.2  Comparable data 
 
Research in specific localities amongst specific BME groups can and does provide 
the valuable data that are necessary to inform the development of local drug 
services, and should be encouraged and expanded.  To begin to obtain a 
comprehensive picture across the EU requires comparable data, however.  This 
would clearly be a difficult undertaking given that: 
 
BME communities are not an homogenous group:  there is a large variety of 
these communities in the EU, cultural variations between them, and, within 
each group, differences between those who were born in another country and 
those born after migration  
 
there is overall lack of ethnic monitoring (as discussed in Section 3.1.1) 
 
drug use amongst many BME groups is hidden and ignored (Sections 3.1 and 
3.2.5) 
 
some risk factors for drug use are specific to some BME groups (Section 
3.2.3) 
 
some researchers and policy-makers in some countries are unwilling to 
address the issue of drug use amongst BME groups (Sections 2.4.1 and 3.1), 
and funding for research may not be forthcoming. 
 
The current study was only the very first step in obtaining comparable data.  A highly  
fruitful next step would be to use the Delphi method:  to devise just one questionnaire 
based on this section's synthesis of the information received for this study, and, using 
the methods described in Section 2, repeat the exercise.  The constraints imposed 
on the current study make it essential that any follow-up is adequately funded and 
has a realistic timeframe in order that, for example, the range and diversity of 
informants can be increased and, where necessary, the questionnaire can be 
translated into BME languages.    
 
Investigations of trends at local, or country, or EU level, or across particular ethnic 
groups are also necessary.  Themes that should be prioritised for future 
investigations should incorporate both quantitative and qualitative research methods, 
and include: 
 
the reasons for the under-representation of BME groups as drug service 
clients, as discussed in Section 3.2.5   
 
whether or not commonly-held beliefs about BME groups - such as strong 
social / family bonds and religion are factors that protect against drug use - 
are accurate (Section 3.2.4) and, if so, how these protective factors operate 
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factors affecting drug-using patterns amongst specific BME groups (Section 
3.2.3), such as selling drugs precedes use amongst those who are socially 
excluded and who are involved in drug distribution as a method of income 
generation  
 
implementation and analysis of the results of ethnic monitoring (Section 3.1.1) 
 
collating examples of good practice in methods of researching drug use and 
the related service needs amongst BME groups, including those obtaining 
information from a wide variety of sources, such as this study (Section 3.3.3) 
 
collating examples of good practice of planning and delivering drug services 
to BME communities, especially those that effectively engage with the 
communities involved (Section 3.4.1). 
 
Such investigations should not neglect those BME groups newly-arrived in the EU;  
those groups that are dispersed throughout a particular country (a characteristic that, 
in the UK, has been found to apply particularly to the Chinese population);  nor those 
BME groups that are not officially regarded as such in the countries where they live 
(such as all groups except the 'Muslim minority' in Greece and Gypsies in Spain).    
 
 
Qualitative research 
 
As noted by Hartnoll (2000:13), "Qualitative research focuses on the meanings, 
perceptions, processes and contexts of the 'world of drugs' and offers ways of 
understanding drug use patterns and related responses."   In this study, the 
knowledge base on the drug use of BME groups and related issues in some 
countries - particularly those in which ethnic monitoring cannot or is not conducted - 
has been especially enhanced by the results of qualitative research studies.  In the 
discussion of future directions necessary for progress to be made in the development 
of drug services for BME groups in most of the countries covered by this study 
(Volume 2), it is stressed that the necessary research should include (or continue to 
use) qualitative research to, for example, examine the drug use of BME groups in 
relation to the link between drug use and social exclusion, and to barriers to drug 
service access and uptake.   
 
Before any such research is undertaken, however, the characteristics of both those 
who conduct the investigations and those who are asked for information are crucial 
considerations.  
 
 
3.3.3  Researchers and informants 
 
Several disadvantages to the usual methods of conducting research on drug use and 
the related service needs amongst BME communities have been revealed by this 
study: 
 
Although this report represents the very first stage of a needs assessment 
concerning the drug use of BME groups throughout the EU, it is significant 
that almost two-thirds of respondents were from drug services or drug 
research organisations / universities.  As discussed in Section 2.4.3, valuable 
though information from these sources is, the relevant knowledge is not 
exclusive to them.  The method used to collect data for this study 
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extended well beyond these fields to include those involved in other aspects 
in the health and welfare of BME communities, such as BME community 
organisations, general health and social services, social workers, the police, 
regional and local government services, youth services, and so on.  However, 
it appears that few drug researchers and drug services have contacts outside 
their own professional field.   
 
As pointed out by Patel (2000), in the UK, the usual method of conducting 
drug needs assessments amongst BME groups consists of commissioning 
researchers who 'parachute' into the relevant local communities, ask about 
their drug-related needs, raise expectations that there will be some change, 
but disappear to produce a needs assessment that has no long-term impact.  
 
In the UK, there is a history of failure to include potential clients in the 
planning and delivery of drug services, especially those from BME 
communities.  It has been shown that many BME community organisations / 
groups do not feel able to form effective partnerships with statutory bodies 
(Sangster et al, 2002) and many of the methods of 'consulting' BME 
communities (such as talking to religious leaders and those who were 
established as traditional leaders during the first waves of immigration) often 
leave more isolated individuals, families, and communities unrepresented:  
this is particularly the case in relation to consultation with BME drug users.  
 
A solution to these problems is illustrated by a project from the UK, The Black and 
minority ethnic community drugs misuse needs assessment project (Buffin et al, 
2002), an initiative from the Department of Health (DH) and the Centre for Ethnicity 
and Health, University of Central Lancashire.  This radical and highly successful 
project used BME community groups (ie  local groups that provide some sort of 
service for their community - social welfare rights advice, refugee groups, religious 
groups, groups that provide education in addition to school, language classes, social 
events, child care, lunches for elderly people, and so on) as researchers.  
 
In order to avoid the 'parachuting' model discussed above, the DH wanted 
local BME community groups to undertake drugs needs assessments 
themselves:  it was seen as a missed opportunity that the resources 
employed in traditional needs assessment processes neither involve nor 
benefit the communities whose needs are being assessed.  It was recognised 
that these groups were probably not familiar with drug use and the related 
service issues, and that they were unlikely to have any experience of 
conducting a needs assessment.  However, as community groups, they had 
access to their local communities, the potential to be supported and trained, 
and could work in a culturally-sensitive manner.  In addition, members of the 
groups were familiar with the language and the culture of their communities.  
Therefore, even where drug use was a taboo subject and hidden to avoid 
stigmatisation, the groups were far less threatening to potential informants 
and more likely to obtain information than an investigator who was a stranger, 
white, and a professional researcher.  
 
The project recruited, trained (in drugs awareness and research methods) 
and supported 47 BME community groups - representing 25 different 
ethnicities - to conduct drug needs assessments in their communities in order 
to inform an effective strategic approach by drug policy-makers, service 
commissioners, planners and providers.  The process by which these needs 
assessments were produced was as important as the final output.   
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Partnerships with local service planners and commissioners were an 
essential criteria for participation. A Project Support Team, consisting of a 
total of 13 members of staff from the Centre for Ethnicity and Health was 
established, and was a vital component of the project.  Project support 
workers were required to offer a significant level of support to the community 
groups, but to stop well short of doing the work that the communities were 
learning to do themselves.      
 
By participating in the project, the community groups benefited by learning 
about drug-related issues and about managing and undertaking a needs 
assessment.  In this way, at the end of the project, a number of individuals 
who gained from undertaking this work remained in the community, having 
learned about drugs and the related needs of their communities, and able to 
continue to articulate those needs to their local service planners, 
commissioners and providers.  In some cases, the involvement of local 
individuals in the project resulted in the recruitment of more people from BME 
communities into local drug services and into other related statutory and 
voluntary sector roles where BME communities are under-represented. 
  
As a result of this project, the Community Engagement Agency (CEA) has been 
established to act as a continuing focus to develop and support capacity building in 
BME communities in England, and the Centre for Ethnicity and Health are currently 
developing a model of community engagement. 
 
 
3.3.4  Dissemination of information 
 
This study has revealed the many gaps in the knowledge base concerning the drug 
use of BME groups in the EU and the related drug service issues.  This situation is 
not helped by the lack of dissemination of the information that is available.  The study 
heard about several apparently major relevant research projects, but details proved 
difficult locate and they were not all reported by informants from the relevant 
countries.  Comprehensive dissemination of information should not be restricted to 
drug research organisations and academics in the drug field, but include policy-
makers, social workers, youth workers, national and European agencies, BME 
community organisations, and drug service planners, commissioners and providers.  
A database of those contacted for this study has been established, and this should 
be kept up-to-date, expanded, and utilised for this purpose. 
 
 
 
3.4  Drug service development 
 
This section discusses how drug services can be developed to meet the needs of 
BME communities in the EU, providing examples of good practice to illustrate the 
way forward. 
 
Many BME groups are already socially excluded:  failure to consider their drug 
service needs exacerbates this situation.  Although there is considerable variation in 
the drug services provided for BME groups both within and between member states, 
across the EU as a whole, drug policy and practice reflect the needs of the white 
indigenous population.  For progress to be made in the development of drug services 
for BME groups, in each of the 16 countries covered by this study there is a need for 
the implementation (or improvement) of ethnic monitoring (Section 3.1.1) and 
 43
 targeted needs assessments that engage BME communities (as described in The 
Black and minority ethnic community drugs misuse needs assessment project  in 
Section 3.3.3).   
 
The lack of uptake of drug services by BME groups is reflected in the drug service 
client statistics (Section 3.2.2) which reveal that, with very few exceptions, every 
BME group in the EU is under-represented.  Nevertheless, the information gathered 
for this study has shown that the potential for members of BME groups to develop 
drug problems is the same as it is for the rest of the population (Section 3.2.3).  
However, to be successful, responses may have to be different.  Two major reasons 
for this are the barriers to service access faced by BME groups (Section 3.2.5) and 
the factors specifically affecting drug use amongst them (Section 3.2.3).  Therefore, 
ethnic monitoring and targeted needs assessments must address these issues and 
suggest appropriate responses.   
 
These initiatives can be best illustrated by examples of good practice that were 
reported to this study.   
 
 
3.4.1  Drug services for Black and minority ethnic communities:  examples of 
good practice 
  
It is highly appropriate that this section begins with details of the Race Relations 
(Amendment) Act 2000, that came into force in the UK in April 2001, and places a 
general duty on public authorities to promote race equality.  The Act creates a clear 
expectation that these authorities will review their functions and identify steps to be 
taken to comply with the new provisions, and can be used as a template for the 
development of services for BME groups in other countries.   
 
The Act challenges all public services to eradicate discrimination and disadvantage 
and it requires public organisations to have clear race equality action plans.  This 
provides the impetus for drug services to address the shortfalls in the provision of 
appropriate and accessible services for BME groups.  The Act specifically seeks to 
address institutional racism, defined by Macpherson (1999:9) as: 
 
'The collective failure of an organisation to provide an appropriate and 
professional service to people because of their colour, culture, or ethnic 
origin.  It can be seen or detected in processes, attitudes and behaviour 
which amount to discrimination through unwitting prejudice, ignorance, 
thoughtlessness and racist stereotyping which disadvantage minority ethnic 
people.' 
 
In relation to drug services, this provides a benchmark from which to examine the 
current situation:  an understanding of the social, political, and economic structures  
within which racism is constructed and experienced is crucial when planning service 
delivery and the Commission for Racial Equality (CRE, 2000) has provided 
guidelines to assist public authorities in implementing the Race Relations 
(Amendment) Act 2000.   Briefly, these are: 
 
Definition 
Define all your functions - what you must do, and what you can do.  Then identify - 
by ethnicity and other relevant criteria - the people for whom you should be 
providing various services. 
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Consultation 
Talk to your employees and to the people affected by your policies and practices, 
including people from ethnic minorities.  Listen to their concerns and pay attention 
to their perceptions of your organisation’s stand on racism and racial equality. 
 
Monitoring 
Set up systems to monitor your workforce and the outcomes of your policies 
and practices. 
 
Assessment 
Examine the impact of your policies and ask whether all ethnic groups are being 
treated fairly.  Do they have equal opportunities and equal access to benefits, 
facilities and services?  If not, why not? 
  
Change 
Where the evidence from monitoring shows unequal outcomes between different 
ethnic groups, consider what changes are needed, and take action to prevent 
direct or indirect discrimination and to promote greater equality. 
 
Implementation 
Where your organisation already has good policies on racial equality, make 
sure they are understood and put into practice at every level within the 
organisation.  The policies should also be reinforced through staff 
performance appraisals and disciplinary procedures. 
 
 
In the country profiles in Volume 2, there are examples of large and small initiatives 
that are attempting to engage with BME groups.  As an illustration, some of these are 
presented in this section.  As informants to this study were not specifically questioned 
on this issue, there are many other examples (see, for example, EMCDDA's previous 
work on this issue – Khan et al, 2000;  AC Company, 1999 and 2001;  the EDDRA 
database -  http://www.emcdda.org/responses/methods_tools/eddra.shtm) and 
doubtless many more are continuously being planned and implemented.  In some 
cases, few details of the service noted below were provided.  However, it is 
noticeable that an essential element of many of the examples for which details were 
available is the involvement of the targeted BME community in the planning and 
delivery of the service in question. 
 
 
Finland 
 
There has been a recent focus of targeting services at Russian-speaking groups, 
although these activities are in their early stages. 
 
 
France 
 
Espoir Goutte d'Or 
 
In France, the strict legislation surrounding BME-targeted services appears to have 
been overcome by Espoir Goutte d'Or (EGO).  This drug service is based in the 
Goutte d'Or district of Paris, a well-known drug-using and dealing area and also 
home to a large population of Maghrebians, other Black Africans and Dom-Tom.   
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Thus, the majority of EGO's clients are from these communities.  The project 
operates by involving all members of the community in all its activities, and is a focal 
point and mutual aid network around drug use and HIV / AIDS.  EGO offers a range 
of social and health services - including a needle exchange - and training in 
community work, AIDS and hepatitis prevention, and the reduction of drug-related 
harm.    
 
 
Greece 
 
Drug advice services have been set up for Russians via the INTEGRA / KETHEA 
programme in the Psychiatric Hospital of Thessasloniki. 
 
 
Netherlands 
 
The Arrazi Prevention Project 
 
The Arazzi Prevention Project was initiated as a response to the concern over drug 
use and criminality amongst adolescent Moroccan boys in the Netherlands and 
because it is commonly assumed that their parents lack knowledge about drugs and 
about drug services.  Though a decrease of drug-related problems amongst these 
boys is a long-term target, the first step was the development and implementation of 
a series of education course initiated in co-operation with Moroccan interest groups.  
The courses aimed to enhance discussions about drugs and crime amongst 
Moroccan families in specific Amsterdam neighbourhoods, and to inform parents 
about drug services. 
 
An evaluation of the project revealed that its importance was stressed by almost all 
the parents, especially because it was initiated by Moroccan interest groups and  
targeted parents.  More than 80% of those who attended the courses thought that 
there should be more discussion about drugs and crime in their community, whereas 
only 47% of non-participants agreed.  Participants strongly expressed that the 
courses should continue, but that organising these in co-operation with Moroccan 
interest groups had to be a prerequisite. 
 
Experimental project for North-African drug users in Rotterdam 
 
In Rotterdam, 12 - 15% of 'street junkies' are of North African origin, and most of 
them are illegal immigrants.  This group were considered to be at very high risk of 
sexually-transmitted diseases, as they are characterised by injecting heroin use and 
prostitution;  regarded as very hard for drug services to reach;  and drug use and 
sexual activity is not discussed amongst members of their families and community.  
Preventive activities amongst this population are sparse, but an experimental peer 
support project was conducted amongst them.  An evaluation shows that, of thirty-
five potential peer supporters (all male), eight were chosen to be trained and, 
between them, contacted 595 male drug users, three-quarters of whom had never 
had contact with drug services in Rotterdam.  The peer support offered included 
information about drugs and drug services, and the distribution of sterile injecting 
equipment.   
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The Tjandu Foundation:  'Ethnic Minority Youngsters and Creative Forms in Addiction 
Prevention' 
 
The Tjandu Foundation is the national Moluccan foundation, and has expanded its 
activities from the original Moluccan target group to other BME groups.  The project 
'Ethnic minority youngsters and creative forms in addiction prevention' is based on 
the self-help approach, and has produced manuals for creative and educational 
activities for the Moluccan, Antillian, Turkish, and Moroccan communities.  A film 
about Moluccan drug users has also been produced.   An interim report (Tjandu 
Foundation, 1999) shows a substantial reduction in the number of Moluccans 
dependent on 'hard' drugs. 
 
Other examples of good practice from the Netherlands include: 
 
Some drug treatment centres in Amsterdam have established contact via the 
imams (religious leaders in mosques) to the parents of young North Africans 
males who are at risk of drug use.  This strategy aims at facilitating access to 
help and information from drug services. 
 
Illegal immigrants are offered drug services at St Paul's Church and the 
Boumanhouse in Rotterdam, and by AMOC in Amsterdam. 
 
As discussed in Section 3.2.3, some BME drug users are from countries 
where there are wars, and drug treatment is complicated by the trauma they 
have undergone.  Some drug services in the Netherlands have addressed 
this issue via co-operation with mental health services for asylum seekers. 
 
 
Norway 
 
In Oslo, Uteseksjonen's outreach work includes targeting young members of BME 
groups who are involved in selling and using cannabis in an area of the city also 
frequented by older injecting heroin users.  These young people have problems 
including those related to drugs, and are at risk of problematic drug use.  A report is 
currently being prepared on this, and focuses on young people (mainly Somalis) and 
the process of marginalisation (Kuvoame and Dugstad, forthcoming). 
 
Rusmiddeletaten (Agency for the Prevention and Treatment of Drug and Alcohol 
Problems) is concerned about the drug use of the second generation of BME groups 
and is funding a drug prevention project targeting this group. 
 
 
Portugal 
 
The importance of the family in the Gypsy community in Portugal led to the belief that 
Gypsy drug users would be more receptive to family, rather than individual, therapy.  
A successful family therapy programme has therefore been established in a drug 
service in the country. 
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Spain 
 
There is evidence that few Gypsies in Spain attend abstinence-based treatment 
programmes, preferring treatment with methadone.  Recently, some drug services in 
Spain have been lessening the regulations on treatment with methadone in an effort 
to attract more Gypsy clients. 
 
 
UK 
 
Packages to support drug treatment services organisational reviews on diversity 
 
In the UK, the National Treatment Agency (NTA) acknowledges that a number of 
groups are currently under-represented in drug treatment, and is committed to 
addressing this and to ensuring that drug treatment services are more inclusive.  The 
NTA has, within its corporate plan, objectives to increase the numbers of currently 
under-represented groups accessing and remaining in treatment, and to improving 
the quality of treatment for these groups.  As part of this commitment, the NTA is 
leading a series of major initiatives to improve the quality and quantity of treatment, 
including an initiative on diversity. 
 
The scope of the project is to provide a package of support to drug treatment 
services to enable them to improve the quality of services to currently under-
represented groups.  Over 2002 - 2003,  eight selected services are acting as pilots 
and pathfinders for developing this package of support.  The project is designed to 
work on a partnership basis and the practical commitment of each selected drug 
treatment service is crucial:  this varies according to each organisation, its size, remit 
and experience in addressing diversity issues.  Thus, the initiative is not being 'done 
to' the services.  The project is a collaborative process in which the project managers 
work with and alongside the pilot treatment services, providing expert guidance and 
support over a sustained period.  This co-operative approach is especially needed 
during the process of organisational review and the development of a template for 
change.  Based on lessons learned, the NTA intends subsequently to roll out models 
of best practice, guidance and support to drug treatment services nationally. 
 
 
The Southall Community Drugs Education Project  
 
The Southall Community Drugs Education Project (SCDEP) (Winters and Dhillon, 
2002) is an on-going project based in an area of London that has a large South Asian 
population, and is also home to other BME communities.  The need for such a project 
had become apparent following national and local research into drug prevention 
issues that highlighted the inaccessibility of drug prevention information, particularly 
to parents in South Asian communities.  The project began with three main themes:  
to access BME communities in a sensitive manner;  to engage young people;  and to 
raise awareness within a wide range of voluntary, community and religious 
organisations, as well as amongst families.  
 
The SCDEP project's aims were achieved via high-profile publicisation of the project;  
a young person's panel;  through volunteers who were trained to deliver drugs 
awareness education to families;  and work with professionals, business leaders, 
voluntary organisations, and religious groups.  This approach provided the 
community with ownership of the project, ensured that the voice of young people was 
heard, and laid the foundations for future sustainability via a local management  
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group.  Thus, the whole community was involved in both a needs assessment and 
the response to those needs:  drugs education and awareness were delivered at the 
same time as needs were being discovered, and stigmatisation was thus avoided.    
 
Many other successful initiatives in the UK are detailed in Fountain et al (2002) and 
Sangster et al (2002). 
 
 
3.4.2  Evaluation and dissemination 
 
Evaluation should be a key component of all drug services for BME groups, and an 
EU-wide database of such initiatives would ensure that lessons can be learned from 
their successes and failures.   
 
In the same way that information about drug use amongst BME communities should 
be widely disseminated (Section 3.3.4), so should examples of relevant good practice 
amongst drug services.  
  
 
 
3.5  Key points for policy-makers 
 
The key points arising from the results of this study for policy-makers at local, 
national and EU-wide levels are: 
 
• Drug use amongst Black and minority ethnic (BME) groups is under-researched, 
and the knowledge base is distorted by an under-representation of many of these 
groups in the statistics on drug service uptake, and their over-representation in 
drug law offence statistics.  
 
 
• There is a lack of prevalence estimates of drug use amongst BME communities,  
they are under-represented in drug services, and there is a lack of recognition that 
drugs are used by them.  This combination means that acknowledgement that 
there is drug use amongst these communities is an extremely important stage in 
the development of responses.  The lack of evidence of the prevalence of drug 
use can be used as a justification not to address it, yet it is only through 
acknowledging it that debate and further investigation can be initiated.  The way 
will then be paved for responses that will support BME communities through drugs 
and drug service education and awareness-raising activities.  Needs assessments 
can then take place alongside changes within drug services, and, ultimately, 
evidence of prevalence and drug service uptake and retention can be 
systematically acquired.  This process should be monitored throughout via drug 
service commissioning systems, to ensure that the needs of the BME population is 
being identified and appropriate responses are being implemented.   
 
• Consistent, co-ordinated ethnic monitoring by drug researchers and drug service 
providers, based on a common set of classifications, is a reliable instrument to 
measure drug service use and, importantly, non-use, by drug users.  Analysis of 
results provide a baseline for improvements to the quality of service provision -  
including equal access for all drug users and more equitable allocation of 
resources - and can be used to track changes in drug-using patterns and in the 
uptake of drug services. 
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• Although there are some cultural variations and some risk factors specifically 
affecting drug use amongst BME groups, their drug-using patterns do not appear 
to be different from those of other socially-excluded groups.  However, this does 
not mean that BME groups can simply 'slot into' existing drug services.  
Responses may have to be different in order that the barriers to drug service 
access faced by BME communities are overcome.  Examples of alternative drug 
treatment approaches include, for example, the use of ethnic healing systems and 
using healers within the community as primary care service deliverers.      
 
• Comparable data should be collected on the following issues by both quantitative 
and qualitative research methods, and the results used to inform the development 
of appropriate drug service provision: 
 
the reasons for the under-representation of BME groups as drug service 
clients 
 
whether or not commonly-held beliefs about BME groups - such as strong 
social / family bonds and religion are factors that protect against drug use - 
are accurate  
 
factors affecting drug-using patterns amongst specific BME groups 
 
implementation and analysis of the results of ethnic monitoring 
 
examples of good practice in methods of researching drug use and the 
related service needs amongst BME groups, including those obtaining 
information from a wide variety of sources  
 
examples of good practice of planning and delivering drug services to BME 
communities, especially those that effectively engage with the communities 
involved. 
 
• Given the link between drug use and social exclusion, drug policy development 
should include making wider linkages to other health, social and regeneration 
agendas, especially those programmes tackling sexual health and poverty. 
  
• Given the gaps in the knowledge base on the drug use of, and related service 
provision for, BME groups, research results and examples of good practice 
amongst drug services should be widely disseminated.   
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